MONTREAL, June 18, 2021 / CNW / – Lumiera Health Inc. (TSXV: NHP) (the “Company” or “Light “), a company specializing in the development and marketing of natural health products, announces its intention to sell, through a private placement, in one or more tranches, up to 52,000,000 units (the” Units “) at the price of $ 0.025 per Unit, for gross proceeds accruing to the Company up to $ 1.3 million. The issue price of the units is equal to the closing price of the Lumiera shares on the TSX Venture Exchange on June 17, 2021.

Each unit will consist of one common share of the capital of the Company (each, an “ordinary share”) and one common share subscription warrant (each, a “subscription warrant”), each warrant entitling the holder to acquire one additional ordinary share, at an exercise price of $ 0.06 per share, for a period of four years from the date of issue.

The Company intends to include an acceleration clause in the certificates representing the warrants under which the Company may accelerate the expiration of such warrants at any time prior to the expiration date in the event where the daily volume weighted average price of the Company’s common shares on the TSX Venture Exchange exceeds $ 0.12 for at least 10 consecutive trading days by notifying in writing the holders of the warrants (the “Acceleration noticeThe Warrants, unless exercised, will expire on the 30th day after the Company provides the notice of acceleration.

The Company may pay registered brokers a cash commission equivalent to a maximum of 7.5% of the total proceeds raised under the private placement and issue broker warrants allowing such brokers to purchase a number of units. equal to a maximum of 7.5% of the total number of units. issued within the framework of the private placement, at the same issue price as the units. Final terms of the Broker Warrants will be confirmed prior to Closing.

The offer should close on or before July 9, 2021. The net proceeds of the private placement are intended to be used for working capital to support income growth and for general corporate purposes. “We have made great strides in the past two months and the additional capital will allow us to accelerate our growth as we continue on our way to profitability,” said Carlos ponce, CEO of Lumiera.

The closing of the private placement is subject to certain standard conditions, including, but not limited to, receipt of all necessary approvals, including acceptance by the TSX Venture Exchange.

For more information on Lumiera, visit

About Lumiera Santé

Lumiera specializes in the development and commercialization of evidence-based botanical products for the healthcare industry. The company sells oral and topical botanicals to help manage unmet medical needs through its Holizen Laboratories division. Lumiera also develops and markets a unique portfolio of products acting on the endocannabinoid system and providing innovative solutions for chronic pain and inflammation. The company is a pioneer in health and pain management innovation and the Lumiera brand is rooted in the brand’s core values ​​of science, nature and compassion. Passionate about helping people feel better, we offer reliable, scientifically proven solutions that work with the body’s own system. For more information visit:

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking information

Certain statements contained in this press release constitute “forward-looking information” as that term is defined in applicable Canadian securities legislation. The words “may”, “would”, “could”, “should”, “potential”, “will”, “seek”, “intend”, “plan”, “anticipate”, “believe”, ” estimate “,” expect “and similar expressions indicate such” forward-looking information “with respect to Lumiera. All statements other than statements of historical fact may be forward-looking information. These statements reflect Lumiera’s current views and intentions with respect to future events, and current information available to Lumiera, and are subject to certain risks, uncertainties and assumptions. These risks and uncertainties include, among others, the risk factors included in Lumiera’s annual MD&A for the year ended. November 30, 2020, which is available under the issuer’s SEDAR profile at Important factors or assumptions have been applied to provide forward-looking information. Many factors could cause actual results, performance or achievements that may be expressed or implied by such forward-looking information to differ from those described in this document if one or more of these risks or uncertainties materialize. If any factor unexpectedly affects Lumiera, or if the assumptions underlying the forward-looking information prove to be incorrect, actual results or events could differ materially from expected results or events. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. In addition, Lumiera assumes no responsibility for the accuracy or completeness of this forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and Lumiera assumes no obligation to publicly update or revise any forward-looking information, except as required by applicable law.

SOURCE Lumiera Health Inc.

For further information: Lumiera Santé Inc., Simon Castonguay, Interim Chief Financial Officer, 514-880-7772, [email protected]

Source link